Creative Medical Technology Holdings Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Creative Medical Technology Holdings de 72.7% y 86.8% respectivamente, mientras que el BPA crecerá en un 63.3% al año.

Información clave

72.7%

Tasa de crecimiento de los beneficios

63.3%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	28.4%
Tasa de crecimiento de los ingresos	86.8%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	13 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:CELZ - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	N/A	-6	N/A	N/A	1
12/31/2025	N/A	-4	N/A	N/A	1
12/31/2024	N/A	-5	N/A	N/A	1
9/30/2024	0	-5	-5	-5	N/A
6/30/2024	0	-6	-6	-6	N/A
3/31/2024	0	-5	-5	-5	N/A
12/31/2023	0	-5	-8	-8	N/A
9/30/2023	0	-10	-10	-10	N/A
6/30/2023	0	-9	-9	-9	N/A
3/31/2023	0	-10	-10	-10	N/A
12/31/2022	0	-10	-8	-8	N/A
9/30/2022	0	-8	-5	-5	N/A
6/30/2022	0	-9	-5	-5	N/A
3/31/2022	0	-10	-3	-3	N/A
12/31/2021	0	19	-2	-2	N/A
9/30/2021	0	-16	-1	-1	N/A
6/30/2021	0	-13	-1	-1	N/A
3/31/2021	0	-12	-1	-1	N/A
12/31/2020	0	-36	-1	0	N/A
9/30/2020	0	-3	-1	-1	N/A
6/30/2020	0	-6	-1	-1	N/A
3/31/2020	0	-4	-1	-1	N/A
12/31/2019	0	-8	-1	-1	N/A
9/30/2019	0	-1	-1	-1	N/A
6/30/2019	0	-1	-1	-1	N/A
3/31/2019	0	-7	-1	-1	N/A
12/31/2018	0	-14	-1	-1	N/A
9/30/2018	0	-17	-1	-1	N/A
6/30/2018	0	-16	N/A	-1	N/A
3/31/2018	0	-10	N/A	-1	N/A
12/31/2017	0	-3	N/A	-1	N/A
9/30/2017	N/A	-1	N/A	-1	N/A
6/30/2017	N/A	-2	N/A	-1	N/A
3/31/2017	N/A	-1	N/A	-1	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que CELZ sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.6%).

Beneficios vs. Mercado: Se prevé que CELZ sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que CELZ sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que CELZ no tenga ingresos el año que viene.

Ingresos de alto crecimiento: Se prevé que CELZ no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de CELZ se prevé que sea elevada dentro de 3 años.

Creative Medical Technology Holdings Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment

New minor risk - Shareholder dilution

Creative Medical Technology Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $1.85 million.

Creative Medical Technology Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $1.85 million.

New minor risk - Share price stability

Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin

Creative Medical Technology Holdings, Inc., Annual General Meeting, Jul 19, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

Creative Medical Technology Holdings Inc. Announces FDA Authorization for Type 1 Diabetes Prevention Therapy Under Expanded Access

Creative Medical Technology Holdings, Inc. Receives Clearance from the FDA to Conduct a Phase 1/2 Clinical Trial Using Their Innovative StemSpine Treatment Known as AlloStem

New major risk - Financial position

Creative Medical Technology Holdings, Inc., Annual General Meeting, Dec 20, 2023

Creative Medical Technology Holdings, Inc. Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Stemspine(R) Using Allostem(Tm) (Celz-201-Ddt) Novel Cell Therapy to Treat Chronic Lower Back Pain

Creative Medical Technology Holdings Receives FDA Clearance to Initiate A Phase 1/2 Clinical Trial of Stemspine® Using Allostem™ (Celz-201-Ddt) for the Treatment of Chronic Lower Back Pain

Creative Medical Technology Holdings Regains Compliance with Nasdaq Listing Requirements

Creative Medical Technology Holdings, Inc. (NasdaqCM:CELZ) announces an Equity Buyback for $2 million worth of its shares.

Creative Medical Technology Holdings Announces Successful Completion of the First Phase of Its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz(R) Immunotherapy Platform

Creative Medical Technology Holdings, Inc. Announces Next Milestone Achievements in ImmCelz Platform Development

Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell Line

Creative Medical Technology Holdings, Inc. Announces Positive Three-Year Follow-Up Data for the Company's Stemspine Pilot Study

Creative Medical Technology Holdings, Inc. Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Novel Cell Therapy for the Treatment of Type 1 Diabetes

High number of new and inexperienced directors

Creative Medical Technology Holdings, Inc. Announces Fda Clearance of Investigational New Drug (Ind) Application for Allostem(Tm), A Novel Cell Therapy for the Treatment of Type 1 Diabetes

Creative Medical Technology Holdings, Inc., Annual General Meeting, Dec 19, 2022

Creative Medical Technology Holdings, Inc. Develops AlloStem Clinical Cell Line

Creative Medical Technology Announces Positive Top-Line Results for OvaStem® Pilot Study

Creative Medical Technology Holdings Receives Non-Compliance Notice from Nasdaq

Creative Medical Technology Holdings, Inc. announced that it has received $17.000001 million in funding

High number of new and inexperienced directors

Creative Medical Technology Holdings, Inc. Announces Progress in Developing a Reproducible Clinical Grade of the Company's ImmCelz® Product

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Creative Medical Technology Appoints Sahil Nock as Chief Commercial Officer

Creative Medical Technology Appoints Sahil Nock as Chief Commercial Officer

High number of new and inexperienced directors

Creative Medical Technology Holdings Deleted from Other OTC

Less than half of directors are independent

Creative Medical Technology Holdings, Inc. announced that it has received $3.78775 million in funding

Creative Medical Technology Holdings, Inc. announced that it expects to receive $3.788 million in funding

Creative Medical Technology Holdings Identifies Synergy Between Immcelz® Regenerative Immunotherapy and Myeloid Suppressor Cells in Treatment of Type 1 Diabetes

Creative Medical Technology Holdings Expands Neurological Application of ImmCelz® into Parkinson's Disease

FDA Responds to Creative Medical Technology Holdings, Inc. Regarding its ImmCelz® IND for Stroke Treatment

Creative Medical Technology Holdings, Inc. Announces Fda Acknowledgment of Ind Application for Immcelz® to Treat Stroke

Creative Medical Technology Holdings Publishes Efficacy in Pain Reduction and Mobility in Patients with Disc Degenerative Disc Using Stemspine® Personalized Adult Stem Cell Therapy

Creative Medical Technology Holdings Provides Update on ImmCelz® FDA Application

Creative Medical Technology Holdings Files Patent on Prevention of Organ Transplant Rejection Using ImmCelz®

Creative Medical Technology Holdings Identifies Cellular Mechanism of Patented Ovastem® Female Infertility/Ovarian Failure Treatment

Creative Medical Technology Holdings, Inc. Announces the Recruitment of Dr. Caigan Du to the Scientific Advisory Board

Creative Medical Technology Holdings Identifies and Files Patent on Novel Mechanism of Immcelz® Therapeutic Activity

Creative Medical Technology Holdings Inc. Recruits Dr. Boris Reznik to the Scientific Advisory Board

Creative Medical Technology Holdings Inc. Files Investigational New Drug Application with FDA for Treatment of Stroke using ImmCelz® Regenerative Immunotherapy

Creative Medical Technology Holdings Announces Patent Filing Based on Preclinical Data in Model of Heart Attack Using ImmCelz Regenerative Immunotherapy

Creative Medical Technology Holdings Announces Successful Application of ImmCelz® Immunotherapy for Treatment of Stroke

Creative Medical Technology Holdings Files Patent on Induction of Infectious Tolerance by Ex Vivo Reprogrammed Immune Cells Utilizing ImmCelz® Cellular Immunotherapy

Creative Medical Technology Holdings Reports Positive Preclinical Data on ImmCelz® Immunotherapy Product in Rheumatoid Arthritis Model

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento